Global News

[ad_1] A Procter & Gamble (P&G) logo is seen during the 6th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 7, 2023 in Shanghai, China. VCG | Getty Images Procter & Gamble on Tuesday reported mixed quarterly earnings and revenue for its fiscal second quarter of 2024. The company also narrowed its outlook for full-year adjusted earnings per share to a range of $6.37 to $6.43, although its forecast for unadjusted earnings fell due to its plans to write down Gillette and restructure certain markets. Shares of the company rose about 1% in premarket trading. Here's what P&G reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $1.84 adjusted vs. $1.70 expected Revenue: $21.44 billion vs. $21.48 billion expected P&G reported fiscal second-quarter net income attributable to the company of $3.47 billion, or $1.40 p

[ad_1] Pedestrians walk past Yum! Brands Inc. Pizza Hut and KFC restaurants in Shanghai, China. Qilai Shen | Bloomberg | Getty Images China is leaving behind pandemic lockdowns, and U.S. companies like Procter & Gamble , Starbucks and MGM Resorts International say the country's recovery is boosting their overall sales as consumers in their home markets watch their wallets. With its large population and swelling middle class, China is a desirable market for many multinational companies that have seen their U.S. businesses mature. But its zero- Covid policy, which imposed harsh restrictions to stop the spread of the virus, hurt the country's economy — and revenue for the many U.S. companies that sell their goods or services there. After rolling back the policy in December, China's economy grew 4.5% in the first quarter. U.S. companies are reporting that demand in China is returning, boosting their sales at a time when many U.S. consumers are pulling back their spe

[ad_1] A combination package of Procter & Gamble Co. DayQuil Severe and NyQuil Severe brand cold and flu medicine is arranged for a photograph in Tiskilwa, Illinois. Daniel Acker | Bloomberg | Getty Images The main ingredient used in many popular over-the-counter cold and allergy medications doesn't actually work to get rid of nasal congestion, an advisory panel to the Food and Drug Administration declared Tuesday.  In a unanimous vote, 16 advisors said oral versions of phenylephrine – a nasal decongestant found in versions of drugs like Nyquil,  Benadryl, Sudafed and Mucinex – aren't effective at relieving a stuffy nose.  The FDA typically follows the advice of its advisory committees but it is not required to do so. The agency could potentially move to begin a process that removes phenylephrine from the market, which would force manufacturers to pull widely used cough and cold medications from store shelves and reformulate those products.  That could affect Procter